IRIS
ALBANESE, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.802
AS - Asia 2.867
EU - Europa 1.994
Continente sconosciuto - Info sul continente non disponibili 403
SA - Sud America 329
AF - Africa 42
OC - Oceania 6
Totale 20.443
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.714
SG - Singapore 1.485
IT - Italia 642
CN - Cina 433
RU - Federazione Russa 298
BD - Bangladesh 279
BR - Brasile 274
DE - Germania 232
VN - Vietnam 188
UA - Ucraina 180
HK - Hong Kong 177
IE - Irlanda 139
FR - Francia 123
JP - Giappone 98
GB - Regno Unito 96
FI - Finlandia 75
KR - Corea 61
PL - Polonia 61
CA - Canada 47
NL - Olanda 35
SE - Svezia 35
IN - India 30
AR - Argentina 23
ID - Indonesia 18
ES - Italia 17
MX - Messico 17
ZA - Sudafrica 14
IQ - Iraq 12
TR - Turchia 11
BE - Belgio 10
EC - Ecuador 10
UZ - Uzbekistan 10
AT - Austria 9
JM - Giamaica 9
MA - Marocco 9
PH - Filippine 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
TN - Tunisia 7
AU - Australia 6
EG - Egitto 6
AL - Albania 5
CO - Colombia 5
EU - Europa 5
GR - Grecia 5
JO - Giordania 5
RS - Serbia 5
SA - Arabia Saudita 5
TW - Taiwan 5
CH - Svizzera 4
CL - Cile 4
CZ - Repubblica Ceca 4
KG - Kirghizistan 4
MY - Malesia 4
PY - Paraguay 4
VE - Venezuela 4
CR - Costa Rica 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
AZ - Azerbaigian 2
BG - Bulgaria 2
BY - Bielorussia 2
DZ - Algeria 2
HN - Honduras 2
KE - Kenya 2
LT - Lituania 2
PE - Perù 2
QA - Qatar 2
RO - Romania 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CM - Camerun 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PR - Porto Rico 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
VC - Saint Vincent e Grenadine 1
Totale 20.046
Salva come PNG Salva come JPEG
Città #
Woodbridge 3.638
Wilmington 3.337
Houston 3.012
Singapore 560
San Jose 480
Fairfield 477
Ashburn 391
Ann Arbor 280
Council Bluffs 262
Chandler 220
Seattle 198
Cambridge 179
Hong Kong 175
Beijing 160
Rome 148
Jacksonville 145
New York 137
Dublin 136
Colorado Springs 110
Medford 102
Tokyo 89
Los Angeles 86
Santa Clara 85
The Dalles 84
Ho Chi Minh City 68
Milan 65
Buffalo 55
Lawrence 47
Moscow 46
Kraków 45
Hanoi 41
Lauterbourg 41
Dallas 34
Helsinki 34
Zhengzhou 34
Dearborn 32
São Paulo 31
San Diego 29
Menlo Park 25
Atlanta 24
Norwalk 23
Chicago 22
Naples 22
North Bergen 18
Nuremberg 18
Redwood City 18
London 17
Turin 16
Brooklyn 14
Phoenix 14
Toronto 14
Salt Lake City 13
Columbus 12
Frankfurt am Main 12
Boardman 11
Jakarta 11
Miami 11
Orem 11
Philadelphia 11
Redondo Beach 11
Rio de Janeiro 11
Brussels 10
Shanghai 10
Tampa 10
Verona 10
Warsaw 10
Elk Grove Village 9
Guangzhou 9
Johannesburg 9
Lappeenranta 9
Palermo 9
San Francisco 9
Boston 8
Charlotte 8
Haiphong 8
Manchester 8
Monte Vista 8
University Park 8
Amsterdam 7
Munich 7
Newark 7
Tashkent 7
Austin 6
Belo Horizonte 6
Florence 6
Hefei 6
Montreal 6
Palo Alto 6
Paris 6
Roebling 6
Seoul 6
Sterling 6
Stockholm 6
Washington 6
Amman 5
Bologna 5
Cagliari 5
City of London 5
Creede 5
Curitiba 5
Totale 15.734
Salva come PNG Salva come JPEG
Nome #
Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt-Jakob disease 627
Increased cortical excitability after selective REM sleep deprivation in healthy humans: a transcranial magnetic stimulation study 589
Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2 586
Unexpected total recovery in a patient with post-anoxic complete alpha coma predicted by recording of cortical SEPs 522
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML 519
Chronic dopaminergic treatment in restless legs syndrome: Does it affect the autonomic nervous system? 508
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis 507
Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study 488
Predicting seizures in untreated temporal lobe epilepsy using point-process nonlinear models of heartbeat dynamics 485
Effects of epilepsy treatment on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics 473
Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors 472
Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease 464
Unilateral spatial neglect and alien limb phenomenon may be early features of Creutzfeldt-Jakob disease 456
Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires 454
May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis 447
Pure ictal sensory seizures may represent a clinical manifestation of PLEDs 440
Fronto-central monomorphic theta activity as EEG pattern of ictal psychosis 436
Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. 433
Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia 432
Facial diplegia resembling bilateral Ramsay Hunt Syndrome 432
Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study 422
Spasticity as an ictal pattern due to excitotoxic upper motor neuron damage 414
CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? 399
Restless legs syndrome and post polio syndrome: a case-control study 398
May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy? 395
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. 394
Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels 393
Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function 393
Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis 390
Electroencephalography and dementia: a literature review and future perspectives 388
Epstein-Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report 370
Sleep disorders in adult-onset myotonic dystrophy type 1: a controlled polysomnographic study 362
Sleep-wake cycle in the Kennedy's disease: a controlled polysomnographic study and self-reported questionnaires 350
Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson’s disease 322
Feasibility of automated detection of sleep apnea using implantable pacemakers and defibrillators: a comparison with simultaneous polysomnography recording 267
Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: Evidence for ictal sympathetic dysregulation 262
Lower instantaneous entropy of heartbeat dynamics during seizures in untreated temporal lobe epilepsy 243
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis 208
Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction 201
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study 187
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression 179
Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study 174
Functional assessment of outer and middle macular layers in multiple sclerosis 170
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis 126
Poor Adherence to the Mediterranean Diet and Sleep Disturbances Are Associated with Migraine Chronification and Disability among an Adult Population in the Lazio Region, Italy 116
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures 114
Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis 109
Distortion product otoacoustic emissions and their suppression as predictors of peripheral auditory damage in migraine: a case-control study 109
Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study 105
Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients 101
Fampridine improves acute optic neuritis contributing to a long-lasting recovery of nerve function 92
Subclinical cochlear dysfunction in newly diagnosed relapsing-remitting multiple sclerosis 91
Correlation between endometriosis and migraine features: Results from a prospective case-control study 90
Post-COVID-19 Hyposmia Does Not Exhibit Main Neurodegeneration Markers in the Olfactory Pathway 90
Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction 90
Acupuncture Versus Standard Medical Care in the Prophylactic Treatment of Migraine: A Systematic Review and Meta-Analysis 86
Link between gut microbiota dysbiosis and chronic kidney disease 86
One-month atogepant treatment induces rapid changes in delta-band functional connectivity in migraine: an HD-EEG study 72
Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study 71
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography 66
Linking migraine to gut dysbiosis and chronic non-communicable diseases 64
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II) 61
REPLY to "Comment on Correlation between endometriosis and migraine features: Results from a prospective case-control study'': correlation between endometriosis and migraine features is not based on a broad strokes results 61
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 60
Evaluation of the retinal vascular and structural changes in migraine patients treated with anti-CGRP monoclonal antibodies 59
Long-Term Treatment with the Calcitonin Gene-Related Peptide Receptor Antagonist Erenumab in CADASIL: Two Case Reports 55
Inflammatory cytokine signatures are associated with disease burden and comorbidity of episodic migraine and endometriosis 51
Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies 50
Unexpected genomic architecture in a sporadic case of C1-INH Hereditary Angioedema: the hidden heritability 50
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study 49
Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment 48
Early effect of onabotulinumtoxinA on EEG-based functional connectivity in patients with chronic migraine: A pilot study 48
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE) 48
Gut-oriented interventions in patients with multiple sclerosis: fact or fiction? 47
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study) 45
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 42
Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: A multicenter, prospective, cohort study 42
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ) 38
In Alzheimer's disease sleep impairment is correlated with cognitive decline, increased tau and decreased beta-amyloid CSF levels 38
Correlation between epileptiform activity and cerebrospinal fluid biomarkers in Alzheimer's disease 37
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance 36
Redefining migraine prevention: Early treatment with anti-CGRP monoclonal antibodies enhances response in the real world 36
Variable Ophthalmologic Phenotypes Associated with Biallelic Loss-of-Function Variants in POMGNT1 35
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients 33
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study 32
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience 31
Clinical Management of migraine 31
Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study) 31
Alzheimer disease: sleep, orexin and cognitive decline 30
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 study 30
Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review 29
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study) 28
Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence 27
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study 27
Medication overuse and drug addiction: a narrative review from addiction perspective 26
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study) 26
Maintenance of response and predictive factors of one-year GalcanezumAb treatment in Real Life migraine patients in ITaly: the multicenter prospective cohort GARLIT study 26
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study 25
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) 23
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study) 23
Totale 20.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022493 31 22 18 9 40 52 17 22 55 62 18 147
2022/2023665 67 53 51 83 50 136 77 52 54 10 17 15
2023/2024245 38 6 14 8 17 51 11 8 5 27 12 48
2024/20251.989 43 236 128 90 24 230 111 77 113 198 417 322
2025/20264.343 176 108 301 212 204 87 845 502 508 532 419 449
2026/2027306 306 0 0 0 0 0 0 0 0 0 0 0
Totale 20.443